Status:
UNKNOWN
Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study)
Lead Sponsor:
Universität des Saarlandes
Conditions:
Prostate Cancer Metastatic
Castration Resistant Prostatic Cancer
Eligibility:
MALE
18+ years
Brief Summary
This prospective registry aims to assess outcome and toxicity of targeted radionuclide therapies in patients with advanced prostate cancer in clinical routine. While the major investigated treatment m...
Detailed Description
Targeted radionuclide therapy is comprised of different modalities that may be applied in advanced prostate cancer, either targeting bone metastases (mainly using Radium-223), any site of metastases w...
Eligibility Criteria
Inclusion
- Signed informed consent form (Registry Study Inclusion Form)
- Inclusion Criteria for PSMA RLT:
- sufficient tumoral PSMA expression defined as tracer uptake markedly higher than (physiologic) uptake in healthy liver tissue.
- sufficient bone marrow reserve: leukocytes ≥ 2 G/L, platelets \> 75 × 109/L
- sufficient overall patient condition: Eastern Oncology Cooperative Group (ECOG) performance status ≤ 3
Exclusion
- Inability or unwillingness to provide informed consent
Key Trial Info
Start Date :
January 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04833517
Start Date
January 1 2016
End Date
December 31 2025
Last Update
December 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept. of Nuclear Medicine, Saarland University
Homburg, Saarland, Germany, 66421